AZD4547   Click here for help

GtoPdb Ligand ID: 7707

Synonyms: AZD-4547 | KB-74810
PDB Ligand
Compound class: Synthetic organic
Comment: AZD4547 was a fibroblast growth factor receptor (FGFR) tyrosine kinase family inhibitor, investigated as a potential treatment for solid tumours. This compound is now included in AstaZeneca's Open Innovation Pharmacology Toolbox.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 91.51
Molecular weight 463.26
XLogP 4.5
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(CCc2[nH]nc(c2)NC(=O)c2ccc(cc2)N2CC(C)NC(C2)C)cc(c1)OC
Isomeric SMILES COc1cc(CCc2[nH]nc(c2)NC(=O)c2ccc(cc2)N2C[C@H](C)N[C@@H](C2)C)cc(c1)OC
InChI InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
InChI Key VRQMAABPASPXMW-HDICACEKSA-N
No information available.
Summary of Clinical Use Click here for help
AZD4547 is being evalauted in clinical trials for various advanced solid tumour types, in combination with other agents, including the anti-PD-L1 immune checkpoint inhibitor durvalumab. Click here to link to a list of these AZD4547 + durvalumab trials at ClinicalTrials.gov.